Can you provide the last earnings date for ROYALTY PHARMA PLC- CL A?
ROYALTY PHARMA PLC- CL A (RPRX) last reported earnings on 2/11/2026.
ROYALTY PHARMA PLC- CL A (RPRX) Earnings History & Surprises
NASDAQ:RPRX • GB00BMVP7Y09
Current stock price
47.55 USD
-1.02 (-2.1%)
Last:
RPRX Earnings overview
Past quarterly earnings results for ROYALTY PHARMA PLC- CL A (RPRX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $1.23
- Revenue Estimate
- 1.463B
Last Reported
Most Recent- Release Date
- Feb 11, 2026
- Period
- Q4 / 2025
- EPS Reported
- $1.47
- EPS Surprise
- 8.69%
- Revenue Surprise
- -23.38%
Beat Rate
Last 8 Quarters 50%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 1.47 | 1.35 | 8.69% | 27.83% | 621.99M | 811.83M | -23.38% | 4.71% |
| Q3 2025 | 1.17 | 1.06 | 9.99% | 15.84% | 814M | 754.04M | 7.95% | 44.07% |
| Q2 2025 | 1.14 | 1.11 | 3.01% | 18.75% | 727M | 697.73M | 4.20% | 19.57% |
| Q1 2025 | 0.65 | 1.62 | -59.90% | -33.67% | 839M | 765.47M | 9.61% | 47.71% |
| Q4 2024 | 1.15 | 1.08 | 6.88% | - | 594M | 692.47M | -14.22% | -0.34% |
| Q3 2024 | 1.01 | 0.95 | 6.65% | 27.85% | 565M | 710.02M | -20.42% | 5.35% |
| Q2 2024 | 0.96 | 0.98 | -2.47% | 14.29% | 608M | 641.1M | -5.16% | 13.01% |
| Q1 2024 | 0.98 | 1.00 | -2.16% | -38.75% | 568M | 676.48M | -16.04% | -16.96% |
| Q4 2023 | 1.15 | 1.03 | 11.63% | -26.28% | 596M | 705.48M | -15.52% | 5.36% |
| Q3 2023 | 0.79 | 0.77 | 2.45% | 9.72% | 536.313M | 630.35M | -14.92% | -6.48% |
| Q2 2023 | 0.84 | 0.82 | 1.92% | 6.33% | 538M | 547.32M | -1.70% | 0.37% |
| Q1 2023 | 1.60 | 1.30 | 23.19% | 166.67% | 684M | 869.96M | -21.38% | 21.71% |
| Q4 2022 | 1.56 | 1.50 | 3.86% | 95.00% | 565.7M | 970.32M | -41.70% | -1.74% |
| Q3 2022 | 0.72 | 0.73 | -1.45% | 323.53% | 573.5M | 598.92M | -4.24% | -2.10% |
| Q2 2022 | 0.79 | 0.80 | -0.86% | -26.85% | 536M | 553.02M | -3.08% | -3.42% |
| Q1 2022 | 0.60 | 0.75 | -19.60% | 233.33% | 562M | 611.75M | -8.13% | -1.92% |
| Q4 2021 | 0.80 | 0.79 | 1.20% | 185.71% | 575.7M | 567.42M | 1.46% | 0.63% |
| Q3 2021 | 0.17 | 0.71 | -75.92% | -64.58% | 585.8M | 584.26M | 0.26% | 8.80% |
| Q2 2021 | 1.08 | 0.71 | 52.35% | 47.95% | 555M | 528.25M | 5.06% | 8.63% |
| Q1 2021 | 0.18 | 0.66 | -72.85% | - | 573M | 519.89M | 10.22% | 14.39% |
| Q4 2020 | 0.28 | 0.71 | -60.46% | - | 572.1M | 490.33M | 16.68% | - |
| Q3 2020 | 0.48 | 0.60 | -20.46% | - | 538.4M | 462.23M | 16.48% | - |
| Q2 2020 | 0.73 | 0.62 | 17.60% | - | 510.9M | 478.34M | 6.81% | - |
| Q1 2020 | - | - | 500.9M | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
-9.55%
Max EPS beat (4)
9.99%
Min EPS beat (4)
-59.90%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
-0.41%
Max Revenue beat (4)
9.61%
Min Revenue beat (4)
-23.38%
Analysis
In the last 4 quarters, RPRX has beaten EPS estimates in 3 out of 4 releases
RPRX has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, RPRX reported -9.6% below the EPS estimates on average.
In the last 4 quarters, RPRX reported -0.4% below the revenue estimates on average.
Related analysis
ROYALTY PHARMA PLC- CL A / RPRX Earnings FAQ
Did RPRX stock beat earnings estimates in the most recent quarter?
ROYALTY PHARMA PLC- CL A (RPRX) beat EPS estimates and missed revenue estimates in the most recent quarter.
What percentage of the time does RPRX stock beat earnings estimates?
In the last 4 quarters, ROYALTY PHARMA PLC- CL A (RPRX) has beaten EPS estimates in 3 out of 4 releases.